Physician @UFmedicine passionate about taking care of and advocating for patients with #sarcoidosis and #ILD. Opinions presented are my own
Joined May 2019
- Tweets1.2K
- Following745
- Followers1.1K
- Likes1.8K
Divya C. Patel retweeted
Presented at #ATS2025:
In the PREDMETH trial, first-line treatment of pulmonary sarcoidosis with methotrexate was noninferior to that with prednisone regarding the change at 24 weeks in the percentage of the predicted forced vital capacity. Full trial results: nej.md/4kdaf0o
Editorial: Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis? nej.md/4mhaHfW
@atscommunity
ALT The unadjusted mean change in the percentage of the predicted forced vital capacity (FVC) in the prednisone and methotrexate groups between baseline and weeks 4, 16, and 24.
Divya C. Patel retweeted
Check out Vivienne Kahlmann, MD, from the Erasmus Medical Center giving us a sneak peek of her paper, "Methotrexate Versus Prednisone as First-line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial", which she will be presenting at #ATS2025 Session A14, on May 18, Room 25, Hall E in the Moscone Center.
You can still register for ATS 2025! Register on-site or get the highlights package: conference.thoracic.org/
Divya C. Patel retweeted
#ATS2025 starts THIS WEEK! Prepare with our 🌟NEW PODCAST🌟 the CP Assembly's roadmap 🗺️ to #ATS2025! Join host Dr. Kerri Johannson as she breaks down must-see sessions at #ATS2025 with Drs. Kerri Aaronson, Justin Oldham, and @suryapbhatt youtu.be/5iVM9_yDXsE
Divya C. Patel retweeted
Congratulations to @Boehringer with top line data on meeting the primary endpoint of the FIBRONEER phase III IPF-study. We are looking forward to learning more about effectiveness and safety data and are cheering on all activities that can provide patients with better treatment.
#NEWS: We’re excited to announce that our Phase III trial in people living with idiopathic pulmonary fibrosis (IPF) met its primary endpoint.
Learn more here: bit.ly/47JWDoB
Divya C. Patel retweeted
Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!!
#CureIPF
boehringer-ingelheim.com/us/…
Divya C. Patel retweeted
#NEWS: We’re excited to announce that our Phase III trial in people living with idiopathic pulmonary fibrosis (IPF) met its primary endpoint.
Learn more here: bit.ly/47JWDoB
Divya C. Patel retweeted
Exciting results of the PREDMETH study #ERScongress. Methotrexate is as effective as Prednisone for pulmonary sarcoidosis after 24 weeks! @ILD_ErasmusMC @ers_ild @antoniuszkh
Divya C. Patel retweeted
One more out from the #GRADS superteam!! "Chest CT provides more information than CXR in determining extent of physiologic impairment in pulmonary sarcoidosis" Kudos Drs Benn, Maier & GRADS investigators
#SaySarcoidosis #BeyondScadding #FundedByNHLBI
doi.org/10.1016/j.chest.2024…
Divya C. Patel retweeted
Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that:
• Progression of ILD is progression irrespective of time since diagnosis
•“despite usual management” should be included in PPF definition
Important for future PPF guidelines.
#ATS2024
Divya C. Patel retweeted
A Review of ACR/CHEST Clinical Practice Guidelines on Treatment of ILD With Systemic Autoimmune Rheumatic Diseases
Watch the full webinar by the Diffuse Lung Disease and Lung Transplant Network: hubs.la/Q02ybG280
#MedEd #MedTwitter #CHEST_ILDTx
Divya C. Patel retweeted
Dr. Paul Wolters underscores the purpose of the diagnostic process. Identification of UIP is critical as it may be a singular unifier. However familial cases of PF may lack a UIP CT pattern. Telomere length is a common and very valuable biomarker that is helpful.
#ATS2024
Divya C. Patel retweeted
🧵 1/ What’s at stake with race-based equations for lung function? Clinical, occupational, and financial reclassifications for millions of patients.
I’m delighted to share this labor of love, published today in @NEJM and unveiled at #ATS2024.
nejm.org/doi/full/10.1056/NE…
Divya C. Patel retweeted
iclaf.org/wp-content/uploads…
#ICLAF2024 program now available and it looks goooooood!
Excited to head to Athens in October and hear the latest advances in our understanding PF and our efforts to #CureIPF
Divya C. Patel retweeted
I’m going to #ATS2024 tomorrow. I’m sitting here googling “do people say ARDSSS or A-R-D-S?” I’m too much of an ophthalmologist for this.
Excited join to address this impt issue #sarcoidosis @EnnisjamesM @YYandtd @obi_ogugua
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients globenewswire.com/news-relea…
Divya C. Patel retweeted
The CP assembly will be announcing the mentoring, international member and early career achievement awards at the annual assembly meeting at #ATS2024.
Join us to find out the winners! 5pm PDT on Monday 5/20/24
🗺️ Marriott Marquis San Diego Pacific Ballroom 21-22 (Level One)
Divya C. Patel retweeted
For those interested in #ILD #multiomics #precisionsmedicine, come attend our midday symposium on Sun 05/19 12PM Room 24A-C. Will give overview of @nih_nhlbi @ThreeLakes_TLF @PFFORG PRECISIONS program and how to get involved
#ATS2024
Divya C. Patel retweeted
This provides a comprehensive overview of diagnosis, treatment options & outcomes of CS, including challenges in diagnosing & the importance of a multidisciplinary approach.
✍🏽 @RichardChengMD @MKIttlesonMD @beaverspharmd @RonBlankstein @pacoebravo @ngilotraMD @rhythmkri
Divya C. Patel retweeted
@AJPLung is delighted to support Sarcoidosis Awareness month and the #SaySarcoidosis campaign with 2 editorials highlighting opportunities for sarcoidosis research. The first is by Dr. Michelle Sharp @mwsharp5 and Dr. Cathy Bonham @CathyBonham
bit.ly/4cQdxE4